Naoko Takebe to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Naoko Takebe has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.029
-
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
Score: 0.029